Pipeline Therapeutics to Participate in Multiple Upcoming Investor Conferences

September 8, 2023 Off By BusinessWire

SAN DIEGO–(BUSINESS WIRE)–Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today participation in the following upcoming investor conferences:

  • Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023, NY, NY:

    • Pipeline management will participate in 1x1s with investors during the conference.
  • UBS Biotechnology Private Company Virtual Symposium, September 20-21, 2023:

    • Carmine Stengone, Pipeline’s CEO, will participate in a fireside chat on Thursday, September 21, 2023, at 10:30am ET.
    • Pipeline management will also participate in 1x1s with investors during the conference.

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. In April 2023, Pipeline announced that it entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen) for its lead program, PIPE-307, a highly selective M1 antagonist, in central nervous system disorders. The Company’s lead wholly-owned program, PIPE-791, an LPA1 receptor antagonist, is advancing through Phase 1 testing to support treatment of neurological diseases.

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Contacts

Company Contact:
Peter Slover

CFO

[email protected]

Investor Contact:
Amy Conrad

[email protected]